OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NCG55

Nova Consumer Group JSC

PharmaceuticalsVerified

Nova Consumer Group JSC has a debt-to-equity ratio of 0.75, indicating a moderate level of leverage, and a current ratio of 1.24, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -61,285,179,030 VND, which raises concerns about its ability to fund operations from core business activities. The company's profitability is weak, with a return on equity of -1.31% and a return on assets of -0.64%, both significantly below the industry median for pharmaceutical companies. These metrics suggest that the company is not generating returns that meet the expectations of its shareholders or effectively utilizing its assets to generate profit. Nova Consumer Group JSC's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. This lack of diversification increases the company's exposure to market-specific risks and could limit its growth potential in new regions. The company's revenue growth is expected to remain flat in the current fiscal year, with no significant improvement projected for the next fiscal year. This is consistent with the company's recent financial performance, which has shown declining profitability and negative operating cash flow. The company faces several risk factors, including liquidity concerns due to its negative net cash position after subtracting total debt. While the risk of dilution is currently low, the company's financial structure and negative cash flow could necessitate future equity or debt financing, which may lead to dilution of existing shareholders' equity. There are no recent events or filings disclosed in the latest financial data that would indicate significant changes in the company's operations or strategic direction. The absence of recent events suggests a stable but stagnant business environment for the company.

30-day price · NCG+300.00 (+2.9%)
Low$10000.00High$11600.00Close$10800.00As of12 May, 00:00 UTC
Profile
CompanyNova Consumer Group JSC
TickerNCG.HNO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Nova Consumer Group JSC is a pharmaceutical company that generates revenue primarily through the production and sale of consumer healthcare products.

Classification. Nova Consumer Group JSC is classified under the Healthcare sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Nova Consumer Group JSC has a debt-to-equity ratio of 0.75, indicating a moderate level of leverage, and a current ratio of 1.24, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -61,285,179,030 VND, which raises concerns about its ability to fund operations from core business activities. The company's profitability is weak, with a return on equity of -1.31% and a return on assets of -0.64%, both significantly below the industry median for pharmaceutical companies. These metrics suggest that the company is not generating returns that meet the expectations of its shareholders or effectively utilizing its assets to generate profit. Nova Consumer Group JSC's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. This lack of diversification increases the company's exposure to market-specific risks and could limit its growth potential in new regions. The company's revenue growth is expected to remain flat in the current fiscal year, with no significant improvement projected for the next fiscal year. This is consistent with the company's recent financial performance, which has shown declining profitability and negative operating cash flow. The company faces several risk factors, including liquidity concerns due to its negative net cash position after subtracting total debt. While the risk of dilution is currently low, the company's financial structure and negative cash flow could necessitate future equity or debt financing, which may lead to dilution of existing shareholders' equity. There are no recent events or filings disclosed in the latest financial data that would indicate significant changes in the company's operations or strategic direction. The absence of recent events suggests a stable but stagnant business environment for the company.
Key takeaways
  • Nova Consumer Group JSC has a moderate debt-to-equity ratio but faces liquidity concerns due to negative operating cash flow.
  • The company's profitability is weak, with negative returns on equity and assets.
  • Revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
  • The company's growth trajectory is flat, with no significant improvement expected in the near term.
  • The risk of dilution is currently low, but the company's financial structure could necessitate future financing.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyVND
Revenue$970.21B
Gross profit$89.65B
Operating income-$9.96B
Net income-$24.69B
R&D
SG&A
D&A
SBC
Operating cash flow-$61.29B
CapEx-$1.91B
Free cash flow$2.45B
Total assets$3.84T
Total liabilities$1.95T
Total equity$1.89T
Cash & equivalents$6.12B
Long-term debt$1.41T
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$3.50T$370.12B$299.55B$362.54B
FY-3$4.88T$312.15B$273.74B$319.91B
FY-2$4.14T-$910.34B-$930.20B-$950.29B
FY-1$4.25T$129.16B$82.87B$166.45B
FY0$4.52T$243.33B$193.00B$288.47B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$3.70T$2.18T$119.48B
FY-3$5.15T$2.92T$16.43B
FY-2$3.88T$1.92T$17.12B
FY-1$3.78T$1.98T$11.00B
FY0$3.93T$2.09T$0.00
PeriodOCFCapExFCFSBC
FY-4-$384.19B-$39.30B$362.54B
FY-3$61.68B-$51.26B$319.91B
FY-2$10.33B-$38.88B-$950.29B
FY-1-$24.35B-$15.86B$166.45B
FY0$230.08B-$12.36B$288.47B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$970.21B-$9.96B-$24.69B$2.45B
FQ-6$1.03T$62.30B$49.74B$72.53B
FQ-5$1.10T$51.34B$39.48B$48.53B
FQ-4$1.15T$25.48B$18.33B$42.94B
FQ-3$1.10T$77.40B$68.27B$95.11B
FQ-2$1.15T$89.87B$80.78B$97.33B
FQ-1$1.08T$35.73B$20.82B$43.38B
FQ0$1.19T$40.33B$23.13B$52.64B
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$3.84T$1.89T$6.12B
FQ-6$3.84T$1.93T$0.00
FQ-5$3.80T$1.97T$3.00B
FQ-4$3.78T$1.98T$11.00B
FQ-3$3.72T$2.05T$0.00
FQ-2$3.74T$2.12T$0.00
FQ-1$3.90T$2.14T$0.00
FQ0$3.93T$2.09T$0.00
PeriodOCFCapExFCFSBC
FQ-7-$61.29B-$1.91B$2.45B
FQ-6-$292.93B-$5.66B$72.53B
FQ-5-$125.52B-$15.55B$48.53B
FQ-4-$24.35B-$15.86B$42.94B
FQ-3$113.98B-$409.7M$95.11B
FQ-2$262.04B-$1.80B$97.33B
FQ-1$178.84B-$8.52B$43.38B
FQ0$230.08B-$12.36B$52.64B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.89T
Net cash-$1.40T
Current ratio1.2
Debt/Equity0.8
ROA-0.6%
ROE-1.3%
Cash conversion2.5%
CapEx/Revenue-0.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricNCGActivity
Op margin-1.0%2.4% medp25 -91.8% · p75 12.5%below median
Net margin-2.5%1.2% medp25 -98.4% · p75 10.4%below median
Gross margin9.2%45.6% medp25 29.8% · p75 66.7%bottom quartile
CapEx / revenue-0.2%-5.2% medp25 -15.8% · p75 -1.7%top quartile
Debt / equity75.0%9.3% medp25 0.1% · p75 43.8%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-13 00:23 UTC#d7742cf6
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 17:17 UTCJob: 02686c39